Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GYPA | P02724 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191243 | 1.00 | TMEM97 (0.46) | TMEM97SIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL11319730 | 0.92 | TMEM97 (0.45) | TMEM97SIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL11319725 | 0.92 | TMEM97 (0.45) | TMEM97SIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL3508958 | 0.87 | TMEM97 (0.45) | TMEM97SIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL25305166 | 0.86 | TMEM97 (0.44) | TMEM97SIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL28302408 | 0.86 | MEN1 (0.43) | TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL24207804 | 0.86 | TMEM97 (0.44) | TMEM97SIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL25303747 | 0.86 | TMEM97 (0.44) | TMEM97SIGMAR1MEN1KMT2ATSHR | |
| SCHEMBL5606199 | 0.85 | TMEM97 (0.48) | TMEM97SIGMAR1TSHRTAAR1ALDH1A1 | |
| SCHEMBL2182755 | 0.85 | TMEM97 (0.48) | TMEM97SIGMAR1TSHRTAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619179-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038944-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
| EP-1061062-B1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVES | DAISO CO LTD (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20040024261-A1 | Process for preparing butanetriol derivative | DAISO CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6620977-B1 | Reacting 1,2,4-butanetriol in multiple steps with specified reagents using selective protection and deprotection of hydroxyl groups | DAISO CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1061062-A1 | PROCESS FOR PRODUCING BUTANETRIOL DERIVATIVE | DAISO CO., LTD. (JP) | 2000-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024261-A1 | Process for preparing butanetriol derivative | CYP4B1, CYP11B2, CYP11B1 | TMEM97 2523/4885SIGMAR1 1760/4885MEN1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.